Skip to content

Evaluation of efficacy and safety of Vitamin C essence combined with photobiological modulation therapy for the treatment of chloasma

Evaluation of efficacy and safety of Vitamin C essence combined with photobiological modulation therapy for the treatment of chloasma - -

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078426
Enrollment
Unknown
Registered
2023-12-07
Start date
2023-03-31
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chloasma

Interventions

Low energy light modulation (yellow light) + vitamin C essence group:590±10nm low-energy light modulation treatment was performed once every two days for 10 minutes, and 20% vitamin C serum was applie
Low energy light modulation (yellow light) + vitamin C matrix group:590±10nm low-energy light modulation treatment was performed once every two days for 10 minutes, and vitamin C matrix was applied af

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) aged 18-60 years old, female; (2) good health status; (3) meet the diagnostic criteria of chloasma; (4) agree to avoid exposure to sunlight during the trial; (5) Willing to comply with the requirements of the trial to complete the whole trial for a total of 3 months, and able to complete the follow-up as required.

Exclusion criteria

Exclusion criteria: 1) pregnant or lactating women; 2) know in advance that you are allergic to daily chemical ingredients, soap, rubber, alcohol, lotion spices or other cosmetics and drugs; 3) skin diseases (such as psoriasis, eczema, psoriasis, skin cancer, etc.), or obvious erythema, sunburn, wound, etc., in or near the test area; 4) subjects who used decolorizers within 2 weeks before the study, used retinoids, tranexamic acid, chemical exfoliation, injection, laser, etc. within 3 months; 5) have participated in a similar clinical trial within 6 months; 6) pregnant or lactating women; 7) female patients taking oral contraceptives; 8) patients with abnormal liver function, renal function or other systemic diseases; 9) patients with high expectations of treatment effect; 10) patients with melasma who have had poor response to conventional first-line treatment.

Design outcomes

Primary

MeasureTime frame
mMASI assessment;PGA assessment;

Secondary

MeasureTime frame
Melasma melanin index (MI value);Chloasma color chroma test (L*a*b* value);TEWL;skin hydration;VISIA testing;Evaluation of patient satisfaction with therapeutic effect;Dermatology Quality of Life Scale;

Countries

China

Contacts

Public ContactXianJiang

Department of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China

jennyxianj@163.com+86 181 8001 9014

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026